Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Plans for ‘stop anywhere’ night buses recommended by government for women’s safety - 2Shredded cheese sold in dozens of states recalled due to potential for metal fragment contamination
- 3Asia's Noteworthy Destinations: A Voyager's Aide
- 4Vaccine committee votes to scrap universal hepatitis B shots for newborns despite outcry from children’s health experts
- 5Gauging the Upsides and downsides of Visas: A Complete Aide
- Manual for Tracking down Spending plan Agreeable Travel Objections
- NASA Artemis 2 astronauts to make historic moon flyby today. Here's what to expect hour by hour (timeline)
- Metropolitan Greatness: The 6 Urban areas for Quality Living in 2024
- NASA astronauts take new moonsuit for a swim | Space photo of the day for Nov. 28, 2025
- Why Cannes Is the Ultimate New Year’s Eve Destination in the South of France’s Off-Season
- 9 African migrants died in freezing temperatures near Morocco-Algeria border
- From Certificate to Dollars: College Majors with Extraordinary Monetary Prizes
- King Charles shares cancer treatment update, says it's a 'personal blessing'
- Terminal cancer diagnosis announced by JFK's granddaughter
